156 related articles for article (PubMed ID: 36601038)
1. Local Treatment of Recurrent Renal Cell Carcinoma May Have a Significant Survival Effect Across All Risk-of-recurrence Groups.
Marconi L; Kuusk T; Capitanio U; Beisland C; Lam T; Pello SF; Stewart GD; Klatte T; Volpe A; Ljungberg B; Dabestani S; Bex A
Eur Urol Open Sci; 2023 Jan; 47():65-72. PubMed ID: 36601038
[TBL] [Abstract][Full Text] [Related]
2. Long-term Outcomes of Follow-up for Initially Localised Clear Cell Renal Cell Carcinoma: RECUR Database Analysis.
Dabestani S; Beisland C; Stewart GD; Bensalah K; Gudmundsson E; Lam TB; Gietzmann W; Zakikhani P; Marconi L; Fernandéz-Pello S; Monagas S; Williams SP; Torbrand C; Powles T; Van Werkhoven E; Meijer R; Volpe A; Staehler M; Ljungberg B; Bex A
Eur Urol Focus; 2019 Sep; 5(5):857-866. PubMed ID: 29525381
[TBL] [Abstract][Full Text] [Related]
3. The Impact of Histological Subtype on the Incidence, Timing, and Patterns of Recurrence in Patients with Renal Cell Carcinoma After Surgery-Results from RECUR Consortium.
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson EO; Lam TB; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Dabestani S; Bex A
Eur Urol Oncol; 2021 Jun; 4(3):473-482. PubMed ID: 33109495
[TBL] [Abstract][Full Text] [Related]
4. Plasma and Urine Free Glycosaminoglycans as Monitoring Biomarkers in Nonmetastatic Renal Cell Carcinoma-A Prospective Cohort Study.
Gatto F; Dabestani S; Bratulic S; Limeta A; Maccari F; Galeotti F; Volpi N; Stierner U; Nielsen J; Lundstam S
Eur Urol Open Sci; 2022 Aug; 42():30-39. PubMed ID: 35911082
[TBL] [Abstract][Full Text] [Related]
5. Should patients with low-risk renal cell carcinoma be followed differently after nephron-sparing surgery vs radical nephrectomy?
Abu-Ghanem Y; Powles T; Capitanio U; Beisland C; Järvinen P; Stewart GD; Gudmundsson E; Lam TBL; Marconi L; Fernandéz-Pello S; Nisen H; Meijer RP; Volpe A; Ljungberg B; Klatte T; Bensalah K; Dabestani S; Bex A
BJU Int; 2021 Sep; 128(3):386-394. PubMed ID: 33794055
[TBL] [Abstract][Full Text] [Related]
6. Radiofrequency ablation versus partial nephrectomy in patients with solitary clinical T1a renal cell carcinoma: comparable oncologic outcomes at a minimum of 5 years of follow-up.
Olweny EO; Park SK; Tan YK; Best SL; Trimmer C; Cadeddu JA
Eur Urol; 2012 Jun; 61(6):1156-61. PubMed ID: 22257424
[TBL] [Abstract][Full Text] [Related]
7. Features associated with recurrence beyond 5 years after nephrectomy and nephron-sparing surgery for renal cell carcinoma: development and internal validation of a risk model (PRELANE score) to predict late recurrence based on a large multicenter database (CORONA/SATURN Project).
Brookman-May S; May M; Shariat SF; Xylinas E; Stief C; Zigeuner R; Chromecki T; Burger M; Wieland WF; Cindolo L; Schips L; De Cobelli O; Rocco B; De Nunzio C; Feciche B; Truss M; Gilfrich C; Pahernik S; Hohenfellner M; Zastrow S; Wirth MP; Novara G; Carini M; Minervini A; Simeone C; Antonelli A; Mirone V; Longo N; Simonato A; Carmignani G; Ficarra V;
Eur Urol; 2013 Sep; 64(3):472-7. PubMed ID: 22748912
[TBL] [Abstract][Full Text] [Related]
8. Clinical T1a Renal Cell Carcinoma, Not Always a Harmless Disease-A National Register Study.
Almdalal T; Sundqvist P; Harmenberg U; Hellström M; Lindskog M; Lindblad P; Lundstam S; Ljungberg B
Eur Urol Open Sci; 2022 May; 39():22-28. PubMed ID: 35528783
[TBL] [Abstract][Full Text] [Related]
9. Survival outcome and treatment response of patients with late relapse from renal cell carcinoma in the era of targeted therapy.
Kroeger N; Choueiri TK; Lee JL; Bjarnason GA; Knox JJ; MacKenzie MJ; Wood L; Srinivas S; Vaishamayan UN; Rha SY; Pal SK; Yuasa T; Donskov F; Agarwal N; Tan MH; Bamias A; Kollmannsberger CK; North SA; Rini BI; Heng DY
Eur Urol; 2014 Jun; 65(6):1086-92. PubMed ID: 23916693
[TBL] [Abstract][Full Text] [Related]
10. Survival and impact of clinical prognostic factors in surgically treated metastatic renal cell carcinoma.
Tosco L; Van Poppel H; Frea B; Gregoraci G; Joniau S
Eur Urol; 2013 Apr; 63(4):646-52. PubMed ID: 23041360
[TBL] [Abstract][Full Text] [Related]
11. Histological subtype of renal cell carcinoma significantly affects survival in the era of partial nephrectomy.
Nguyen DP; Vertosick EA; Corradi RB; Vilaseca A; Benfante NE; Touijer KA; Sjoberg DD; Russo P
Urol Oncol; 2016 Jun; 34(6):259.e1-8. PubMed ID: 26947350
[TBL] [Abstract][Full Text] [Related]
12. Factors affecting survival in 37 consecutive patients undergoing de novo stereotactic radiosurgery for contiguous sites of vertebral body metastasis from renal cell carcinoma.
Sellin JN; Reichardt W; Bishop AJ; Suki D; Rhines LD; Settle SH; Brown PD; Li J; Rao G; Chang EL; Tatsui CE
J Neurosurg Spine; 2015 Jan; 22(1):52-9. PubMed ID: 25360530
[TBL] [Abstract][Full Text] [Related]
13. Renal Cell Carcinoma with Isolated Lymph Node Involvement: Long-term Natural History and Predictors of Oncologic Outcomes Following Surgical Resection.
Gershman B; Moreira DM; Thompson RH; Boorjian SA; Lohse CM; Costello BA; Cheville JC; Leibovich BC
Eur Urol; 2017 Aug; 72(2):300-306. PubMed ID: 28094055
[TBL] [Abstract][Full Text] [Related]
14. Oncological outcomes of surgery for isolated retroperitoneal recurrence in renal cancer patients after radical nephrectomy.
Staník M; Poprach A; Littnerová S; Čapák I; Hulová M; Šebová N; Lakomý R; Jarkovský J; Doležel J
Urol Oncol; 2022 Mar; 40(3):111.e27-111.e34. PubMed ID: 34961683
[TBL] [Abstract][Full Text] [Related]
15. Percutaneous Ablation Versus Surgical Resection for Local Recurrence Following Partial Nephrectomy for Renal Cell Cancer: A Propensity Score Analysis (REPART Study-UroCCR 71).
Brassier M; Khene ZE; Bernhard JC; Dang VT; Ouzaid I; Nouhaud FX; Olivier J; Nedelcu C; Grenier N; Beuzit L; Doumerc N; Bensalah K; Bigot P;
Eur Urol Focus; 2022 Jan; 8(1):210-216. PubMed ID: 33622625
[TBL] [Abstract][Full Text] [Related]
16. Comparison of Partial Versus Radical Nephrectomy Effect on Other-cause Mortality, Cancer-specific Mortality, and 30-day Mortality in Patients Older Than 75 Years.
Marchioni M; Preisser F; Bandini M; Nazzani S; Tian Z; Kapoor A; Cindolo L; Abdollah F; Tilki D; Briganti A; Montorsi F; Shariat SF; Schips L; Karakiewicz PI
Eur Urol Focus; 2019 May; 5(3):467-473. PubMed ID: 29398456
[TBL] [Abstract][Full Text] [Related]
17. Sunitinib Alone or After Nephrectomy for Patients with Metastatic Renal Cell Carcinoma: Is There Still a Role for Cytoreductive Nephrectomy?
Méjean A; Ravaud A; Thezenas S; Chevreau C; Bensalah K; Geoffrois L; Thiery-Vuillemin A; Cormier L; Lang H; Guy L; Gravis G; Rolland F; Linassier C; Lechevallier E; Oudard S; Laguerre B; Gross-Goupil M; Bernhard JC; Colas S; Albiges L; Lebret T; Treluyer JM; Timsit MO; Escudier B
Eur Urol; 2021 Oct; 80(4):417-424. PubMed ID: 34187771
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
[TBL] [Abstract][Full Text] [Related]
19. Transperitoneal Robot-assisted Partial Nephrectomy with Minimum Follow-up of 5 Years: Oncological and Functional Outcomes from a Single Institution.
Bertolo R; Garisto J; Dagenais J; Sagalovich D; Stein R; Fareed K; Gao T; Armanyous S; Fergany A; Lioudis M; Kaouk J
Eur Urol Oncol; 2019 Mar; 2(2):207-213. PubMed ID: 31017098
[TBL] [Abstract][Full Text] [Related]
20. Risk factors for recurrence after surgery in non-metastatic RCC with thrombus: a contemporary multicentre analysis.
Abel EJ; Margulis V; Bauman TM; Karam JA; Christensen WP; Krabbe LM; Haddad A; Golla V; Wood CG
BJU Int; 2016 Jun; 117(6B):E87-94. PubMed ID: 26305276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
